Table of Contents

company-logo

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited

Sun Pharma Advanced Research Dividend Announcement

• Sun Pharma Advanced Research does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Sun Pharma Advanced Research dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Sun Pharma Advanced Research Dividend History

Sun Pharma Advanced Research Dividend Yield

Sun Pharma Advanced Research current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Sun Pharma Advanced Research stock? Use our calculator to estimate your expected dividend yield:

Sun Pharma Advanced Research Financial Ratios

P/E ratio-17.28
PEG ratio0.38
P/B ratio-91.29
ROE-323.18%
Payout ratio0.00%
Current ratio0.32
Quick ratio0.32
Cash Ratio0.02

Sun Pharma Advanced Research Dividend FAQ

Does Sun Pharma Advanced Research stock pay dividends?
Sun Pharma Advanced Research does not currently pay dividends to its shareholders.
Has Sun Pharma Advanced Research ever paid a dividend?
No, Sun Pharma Advanced Research has no a history of paying dividends to its shareholders. Sun Pharma Advanced Research is not known for its dividend payments.
Why doesn't Sun Pharma Advanced Research pay dividends?
There are several potential reasons why Sun Pharma Advanced Research would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Sun Pharma Advanced Research ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Sun Pharma Advanced Research has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Sun Pharma Advanced Research a dividend aristocrat?
Sun Pharma Advanced Research is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Sun Pharma Advanced Research a dividend king?
Sun Pharma Advanced Research is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Sun Pharma Advanced Research a dividend stock?
No, Sun Pharma Advanced Research is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Sun Pharma Advanced Research stocks?
To buy Sun Pharma Advanced Research you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Sun Pharma Advanced Research stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.